
oct pm et
summari rank one world largest pharmaceut compani offer wide rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
rais target
ep estim line
peer-averag ep vs
beat consensu maintain
ep estim deliv sale
growth yoy led strong growth
sever blockbust drug includ prevnar
ibranc eliqui
off-set greater competit elsewher
portfolio expect similar slow growth
scenario due expect loss
exclus lyrica sale despit
yoy due materi improv
margin cog yoy
produc save fund
valuabl yoy increas support
higher margin think
critic improv growth new
approv indic oncolog
sale area show materi promis
view new treatment breast
lung cancer approv scarola
risk assess reflect promin posit
global pharmaceut market afford
import competit oper financi
advantag howev compani still subject
inher risk common pharmaceut compani
relat discoveri develop
regulatori clearanc success commerci
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview one world largest biopharmaceut comani compani
sizeabl research develop depart help develop new medicin howev compani
growth also augment acquisit past made signific acquisit
major biopharmaceut compani warner-lambert pharmacia wyeth
recent acquisit includ hospira septemb mediv septemb
drug portfolio unmatch term breadth depth global drug market view
compani largest sell drug lyrica billion sale treatment nerv pain
epilept seizur prevnar/prevnar vaccin billion key drug includ ibranc
billion treat breast cancer enbrel billion treatment moder sever plaqu
psoriasi rheumatoid arthriti sold outsid canada lipitor billion
cholesterol-low agent largest-sel drug mani year sale fell sharpli
follow expir market exclus novemb
key drug sold includ viagra million male erectil dysfunct norvasc million
antihypertens agent sutent billion kidney cancer premarin million femal
hormon replac treatment benefix million recombin coagul therapi
certain type hemophilia larg number drug gener sale hundr
million encompass treatment wide rang diseas medic condit consum health
care product includ over-the-counter medicin dietari supplement item zoeti anim health unit
spun sharehold
adjust spend total billion billion sale
sale spend downtrend recent year part on-going cost
reduct program may pipelin consist compound total
late-stag phase registr phase clinic trial phase clinic trial
compound includ new treatment wide rang condit includ cancer aid obes
arthriti heart diseas diabet schizophrenia pain
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate accord forecast made iqvia formerli
im key driver emerg market whose aggreg sale project advanc
compound-annual-growth-rate period growth develop market spur rise
standard live grow govern spend health care howev iqvia forecast moder
trend europ sale grow compound-annual-growth-rate period
impact major develop mid-octob acquir rival drugmak wyeth
billion cash stock think acquisit significantli expand exposur
biolog vaccin new pharmaceut market februari acquir king
pharmaceut billion king brought pfizer grow portfolio novel pain treatment
well larg anim health product busi june acquir anacor pharmaceut
billion septemb acquir mediv mdvn billion januari
spun-off anim health busi new separ trade public compani call zoeti
financi trend sale risen billion billion repres
three-year compound annual growth rate sale aid acquisit advers
impact numer prescript drug lose patent protect time period gross margin
declin partli impact patent expir sever drug
adjust ep risen repres three-year compound-annual-growth-rate
although rate sale growth rate period note ep aid
signific share buyback repurchas billion share decemb
board author new billion share repurchas program
cfo evp global
suppli busi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next month posit view
reflect strong novel drug approv activ
see fda posit
brand drug maker repres
lion share sub-industri market
cap view temper expect
continu pressur gener drug price
neg gener drug maker lower
growth overal prescript volum
far year-over-year increas
brand drug price per prescript
around accord iqvia estim
aid strong novel drug approv activ
fda particularli weak year
novel drug approv number
rebound pace
strong growth well approv alreadi
made octob expect strong
pace novel drug approv brand drug
price inflat continu next year
aid estim approxim
year-over-year growth brand pharma
spend year end june
side coin
outlook gener drug price mostli
neg growth gener drug price
averag around neg far
dont expect major near-term
revers trend toward posit price
growth think deflationari trend
mostli driven robust gener drug
approv activ fda custom
consolid rather polit
total gener drug approv hit record
grow year-over-year
increas competit exist gener
view bring price pace
gener approv seem moder
howev approv
august versu
expect moder
deflat howev bring full-on
gener inflat due view
purchas joint ventur
three major drug distributor three largest
 retail pharmaci limit gener maker
abil rais drug price environ
joint ventur account
gener sale estim includ
cardin
walgreen
beyond drug price think prescript
volum growth fall
next year strong gain health insur
growth think
gain harder come
next year unemploy near
all-tim low remov tailwind
prescript volum growth go forward
view assum slower growth
number peopl enrol health insur
plan gener mean slower growth
use total enrol figur eight
largest health insur proxi
estim number individu
famili health insur grew
growth slow
coincid roughli growth
prescript volum far versu
accord iqvia estim
expect slow next year
increas versu rise
composit index year-to-d
octob
rise composit index
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target ep estim
brand peer gener peer ep vs
ahead view partli lower tax rate vs year ago
howev sale growth sale growth forecast due
softer-than-expect sale arthriti drug xeljanz breast cancer drug
ibranc biosimilar competit europ enbrel along continu soft sale
essenti health unit lower gener price sale prevnar fell
 sale intern sale say
compound develop could reach commerci
potenti achiev annual sale separ state
receiv fair valu sale consum health care busi like
retain invest unit howev also left open potenti spin-off
pursu joint ventur unit /jeffrey loo cfa
rais target peer
ep estim set ep vs
ahead estim sale exclud divestitur
hospira infus system rose innov health sale rose strong
eliqui xeljanz sale essenti health sale fell gener
price pressur guid sale ep
use tax rate reiter decis
regard consum healthcar made /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target forward ep
estim ep vs ahead estim
rais ep estim
sale account divestitur hospira infus rose innov
sale rose essenti fell look essenti
sale improv anticip grow biosimilar sale strong
emerg market sale indic strateg decis regard
consum healthcar busi made /jeffrey loo cfa
analyst research note compani news
rais target ep estim
line peer-averag ep vs beat consensu
maintain ep estim deliv sale growth
yoy led strong growth sever blockbust drug includ
prevnar ibranc eliqui off-set greater
competit elsewher portfolio expect similar slow growth
scenario due expect loss exclus lyrica
sale despit weak sale growth adjust pre-tax incom yoy due
materi improv margin cog yoy
produc save fund valuabl yoy increas
support higher margin think critic
improv growth new approv indic oncolog sale
area show materi promis view new treatment breast
lung cancer approv /colin scarola
keep target forward ep
estim brand peer gener peer ep
vs ahead view rais ep estim
aid lower share count repurchas share
lower tax rate juli
remain buy-back program sale fx benefit rose
innov essenti declin sale driven
solid sale growth eliqui ibranc xeljanz
partial off-set declin legaci product howev encourag
increas spend primarili relat advanc
late-stag develop program believ pipelin could produc
blockbust drug view aggress yet note
impact loss exclus product portfolio slow
significantli /jeffrey loo cfa
et cfra keep hold opinion share inc
announc reorgan three busi innov
medicin establish medicin consum health care effect
believ innov medicin account sale think
structur increas possibl spin establish
medicin unit see solid growth innov medicin modest
growth establish medicin consist off-pat drug
activ seek buyer consum health care unit past
year receiv appropri offer separ state
postpon drug price increas effect juli follow public
critic includ comment presid trump ceo spoke
presid trump state deferr give presid opportun
work drug price blueprint price return pre-juli
level end year presid blueprint come
et cfra keep neutral outlook
sub-industri presid trump expect unveil plan
tackl high drug price today believ like focu two area
rebat pharmaci benefit manag pbm get drug firm
discount medicar get scenario believ trump push
portion rebat pbm receiv medicar discount pass
patient anticip trump propos allow medicar negoti
drug price drug firm ban law drug firm blame pbm
signific rise drug price increas rebat
demand pbm hand blame drug manufactur state need
higher rebat discount higher drug list price fda
commission gottlieb indic may examin rebat pbm receiv
potenti kickback potenti medicar negoti tabl
expect share drug firm react favor potenti downward
pressur pbm /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
